Center For Drug Evaluation Of National Medical Products Administration Granted Breakthrough Therapy Designation For Zai Lab's Repotrectinib For Advanced Solid Tumors With NTRK Gene Fusion Who Have Progressed After TRK Tyrosine Kinase Inhibitor Treatment
Portfolio Pulse from Benzinga Newsdesk
The Center for Drug Evaluation of National Medical Products Administration has granted Breakthrough Therapy Designation to Zai Lab's Repotrectinib. The drug is intended for advanced solid tumors with NTRK gene fusion in patients who have progressed after TRK Tyrosine Kinase Inhibitor treatment.
August 30, 2023 | 11:39 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Zai Lab's Repotrectinib has been granted Breakthrough Therapy Designation, which could expedite its development and review process. This could potentially lead to increased revenues for Zai Lab in the future.
The Breakthrough Therapy Designation is granted to expedite the development and review of drugs intended to treat serious conditions and that have shown promising results in early-stage clinical trials. This designation for Zai Lab's Repotrectinib could potentially lead to faster approval and commercialization, which could increase Zai Lab's revenues in the future.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100